Sir,
The current management of Antiphosphospholipid Syndrome (APS) centres on attenuating thepro-coagulant state while balancing the haemorrhagic risks [1] . This approach relies mainly on a thrombo-prophylaxisstrategy rather than targeting pathogenic antiphospholipid antibodies (aPL)-mediated pathways.
Herewith, we report the aPLdisappearance in three patients with APS associated to Systemic Lupus Erythematous (SLE) while on treatment with belimumab, potentially paving the way for development of new targeted therapies for APS. Belimumab is a monoclonal antibody that works by blocking the B-lymphocyte stimulator and avoiding B-cell activation [2] .It is the first biological drug approved for the treatment of autoantibody positiveSLE in active phase, and it has shown its capability to reduce the antibodies levels, including anti-double stranded-DNA [3] . Intriguingly, in murine models of APS in the setting of SLE, Belimumab proved its ability to stop disease progression and to reduce mortality rate [4] . However, its use in APS patients needs further investigation.
After chart-reviewing all the aPL-positive SLE patients treated in our centre with belimumab, investigating the changes in the aPL profile, we identified three patients with diagnosis of SLE[5] and APS (fulfilling Sydney classification criteria)[6] and persistent aPL positivity (confirmed in more than 6 occasions over the previous 5 years before starting Belimumab) in whom we observed aPL disappearance. Clinical characteristics are detailed in Table 1 and aPL testing methodology is detailed in Supplementary Material S1. All patients received belimumab for active SLE (i.v.10 mg/kg at 2-week intervals for the first 3 doses and at 4week intervals thereafter). After 8 months since belimumab was started, Patient#1 became persistently negative for anti-β2-glycoprotein I antibodies (anti-β2GPI), while anti-cardiolipin antibodies (aCL) titre significantly decreased. While on treatment, anti-β2GPI and aCL levels both turned negative in Patient#2. Interestingly, after being on belimumab for one year, she planned a pregnancy and preferred to suspend the treatment, after 8 months since suspension, antiβ2GPI antibodies were detectable again. Patient#3 was persistently negative for aCL while being on belimumab(28 months). When he discontinued the therapy for lack of response, aCL antibodies returned positive after 2 months. Figure 1 illustrates aPL titres of the three patients in relationship with belimumab therapy.Two patients (#1 and #3) persistently tested positive for LA despite Belimumab treatment. No patients experienced hypogammaglobulinemia while on belimumab and IgG/IgM levels were constantly within normal range. Of note, none of the patients was started on a concomitant immunossupressive treatment when Belimumab was begun. However, a synergic role of hydroxycloroquine in the aCL and anti-beta2GPI disappearance cannot be excluded.
Persistent aPL disappearance is a hot topic of discussion in the field of APS, but the clinical significance of sero-negativization is still to be elucidated [7, 8] .At the best of our knowledge, despite its limitations (e.g. sample size and retrospective design), this pilot studyis the first report of aPL negativization after starting therapy with belimumab. Even more interesting, after stopping the treatment (mean time of two months) patients turned to be positive tested for IgG aPL again. The clinical relevance of these findings should be investigated in prospective multicenter studies, but if confirmed, they might modify the therapeutic management of APS patients.Potentially, the current 'anti-thrombotic' approach to APS patients will be at least combinedin the future with an'immunomodulatory' approach. *Defined as Annular scaly plaques, hypopigmentation; scaly erythematous patches, reticulate erythema **Defined asinflammatory arthritis involving more than 3 joints ***Defined as thrombocytopenia (<100.000 platelets X10 9 /L), leucopenia(<2.500 white blood cells X10 9 /L) and anemia (Hemoglobin <9g/dL) **** Defined as thrombocytopenia (<50.000 platelets X10 9 /L), and leucopenia(<3.000 white blood cells X10 9 /L
